Drug Pipeline

AK112 Injection Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
0
Recruiting
1
Phase 3
2
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-09 NCT07636772 A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma Phase 2 Not Yet Recruiting
2026-05-15 NCT07591090 A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06396065 Phase III Study of AK112 for NSCLC Patients Non-Squamous Non-small Cell Lung Cancer Active, Not Recruiting
Phase 2
NCT07591090 A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer Advanced Breast Cancer Not Yet Recruiting
NCT07636772 A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma Urothelial Carcinoma (UC) Not Yet Recruiting
Sponsors Running AK112 Injection Trials
Akeso (2) Summit Therapeutics (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Breast Cancer (1) Bladder Cancer (1)
Get alerts when AK112 Injection trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free